Boardroom Alpha
Boardroom Alpha
MRK · Additional Proxy Materials (DEFA14A) · Filed April 8, 2026

Merck & Co Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
April 8, 2026
Ticker
MRK
Accession
0001193125-26-147718
Boardroom Alpha · Filing insights

Merck's board urges votes for directors and compensation; opposes three proposals on DEI, coverage gaps, and political contributions.

About Merck & Co Inc
Market cap
$366.0B
1Y TSR
+73.4%
3Y TSR
+12.0%
Board grade
B
Sector
Healthcare
CEO
Robert M Davis
Last annual meeting: May 26, 2026 · View full Merck & Co Inc profile →
DEFA14A
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

 

 

Filed by the Registrant         Filed by a Party other than the Registrant 

Check the appropriate box:

 

Preliminary Proxy Statement

 

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

 

Definitive Proxy Statement

 

Definitive Additional Materials

 

Soliciting Material Pursuant to Section 240.14a-12

 

 

LOGO

Merck & Co., Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

 

No fee required.

 

Fee paid previously with preliminary materials.

 

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

 

 
 


LOGO

Your Vote Counts! Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V90969-P46756-Z92129 *Please check the meeting materials for any special requirements for meeting attendance. MERCK & CO., INC. 126 EAST LINCOLN AVENUE RAHWAY, NJ 07065 MERCK & CO., INC. 2026 Annual Meeting Vote by May 25, 2026 11:59 PM ET You invested in MERCK & CO., INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the shareholder meeting to be held on May 26, 2026. Vote Virtually at the Meeting* May 26, 2026 9:00 a.m. Eastern Time Virtually at: www.virtualshareholdermeeting.com/MRK2026 Get informed before you vote View the Notice and Proxy Statement and Annual Report on Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 12, 2026. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639, or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. Merck


LOGO

Vote at www.ProxyVote.com Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. Voting Items Board Recommends V90970-P46756-Z92129 1. Election of Directors Nominees: 1a. Douglas M. Baker, Jr. For 1b. Mary Ellen Coe For 1c. Pamela J. Craig For 1d. Robert M. Davis For 1e. Thomas H. Glocer For 1f. Surendralal L. Karsanbhai For 1g. Risa J. Lavizzo-Mourey, M.D. For 1h. Stephen L. Mayo, Ph.D. For 1i. Paul B. Rothman, M.D. For 1j. Patricia F. Russo For 1k. Christine E. Seidman, M.D. For 1l. Inge G. Thulin For 1m. Kathy J. Warden For 2. Non-binding advisory vote to approve the compensation of our named executive officers. For 3. Ratification of the appointment of the Company’s independent registered public accounting firm for 2026. For 4. Shareholder proposal regarding a report on DEI risks in federal contracting. Against 5. Shareholder proposal regarding a report on healthcare coverage gaps. Against 6. Shareholder proposal regarding a report on political contributions. Against THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote these important matters.

From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Merck & Co Inc (MRK)

Reference

Frequently asked questions

When did Merck & Co Inc file this DEFA14A?
Merck & Co Inc (MRK) filed this Additional Proxy Materials (DEFA14A) with the SEC on April 8, 2026. The accession number assigned by EDGAR is 0001193125-26-147718.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
Merck's board urges votes for directors and compensation; opposes three proposals on DEI, coverage gaps, and political contributions. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Merck & Co Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Merck & Co Inc has filed under CIK 310158, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer